Business Context and Reporting Period
This Form 8-K is filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on May 13, 2021. The report announces financial results and operational updates for the quarter ended March 31, 2021. The company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Select Market under the symbol FREQ.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for specific financial figures.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. It only confirms that operational updates and financial results for the quarter were announced.
Guidance, Outlook, and Risks
The company provided operational updates alongside its financial results, though specific guidance or outlook details are not included in this text. The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liabilities of the Exchange Act unless expressly incorporated by reference.
Investor Verification Checklist
- Verify the correct registrant name is Frequency Therapeutics, Inc., as the input metadata incorrectly listed "Korro Bio, Inc."
- Review Exhibit 99.1 (the Press Release) to obtain actual revenue, net loss, and cash position figures for the quarter ended March 31, 2021.
- Confirm the status of the company as an emerging growth company and its implications for financial reporting standards.
- Check the operational updates mentioned in the press release for progress on clinical trials or product development.